bluebird bio To Present LentiGlobin BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society of Hematology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical studies of LentiGlobin BB305 in beta-thalassemia major and severe sickle cell disease (SCD) will be highlighted in oral and poster presentations at the 57th Annual Meeting of the American Society of Hematology (ASH).

Help employers find you! Check out all the jobs and post your resume.